Europe offers vast opportunities for biopharma companies — but also operational complexity that can delay access and drain internal resources. From disparate regulatory frameworks to multi-country distribution, patient onboarding and post-authorisation responsibilities, launching in Europe is rarely straightforward.
This expert-led webinar explores how biotech and pharma companies are tackling these challenges with leaner, smarter, end-to-end models — not by building everything in-house, and not by handing off control through outlicensing. We examine how integrated commercial partners are helping companies accelerate timelines and reduce risk, offering regulatory clarity, supply chain precision and real-time patient engagement infrastructure across the continent.
We’ll also discuss how digital support tools and embedded patient services can help ensure clinical continuity, support safe decentralised distribution, and generate meaningful real-world insights during and after launch.
In this session, you’ll learn how to:
- Navigate European market entry with a single partner model designed for speed, compliance and scale
- Build integrated early access programmes that connect regulatory approval to real patient delivery
- Coordinate cross-border logistics, local QP release, and pharmacovigilance without expanding internal headcount
- Support post-authorisation activities and track programme success with fit-for-purpose digital tools
- Maximise launch readiness with select real-world data insights, without relying on complex evidence generation frameworks